2022
Network Meta-Analysis Comparing Angiotensin Receptor-Neprilysin Inhibitors, Angiotensin Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors in Heart Failure With Reduced Ejection Fraction
Park D, An S, Attanasio S, Jolly N, Malhotra S, Doukky R, Samsky M, Sen S, Ahmad T, Nanna M, Vij A. Network Meta-Analysis Comparing Angiotensin Receptor-Neprilysin Inhibitors, Angiotensin Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors in Heart Failure With Reduced Ejection Fraction. The American Journal Of Cardiology 2022, 187: 84-92. PMID: 36459752, PMCID: PMC10958453, DOI: 10.1016/j.amjcard.2022.10.026.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBayes TheoremDeathHeart FailureHumansHypotensionNeprilysinNetwork Meta-AnalysisRandomized Controlled Trials as TopicReceptors, AngiotensinStroke VolumeTreatment OutcomeVentricular Dysfunction, LeftConceptsAngiotensin receptor neprilysin inhibitorAngiotensin receptor blockersReduced ejection fractionHeart failureEjection fractionHigh riskCause mortalityReceptor blockersCardiac deathLower riskEnzyme inhibitorsMajor adverse cardiac eventsAngiotensin converting enzyme (ACE) inhibitorsAdverse cardiac eventsEfficacy end pointNetwork meta-analysis approachImproved clinical outcomesRandomized clinical trialsP scoreCardiac eventsAngiotensin receptorsClinical outcomesNeprilysin inhibitorClinical benefitRecent trialsAssessing race and ethnicity differences in outcomes based on GDMT and target NT-proBNP in patients with heart failure with reduced ejection fraction: An analysis of the GUIDE-IT study
Pahuja M, Leifer ES, Clarke JD, Ahmad T, Daubert MA, Mark DB, Cooper L, Desvigne-Nickens P, Fiuzat M, Adams K, Ezekowitz J, Whellan DJ, Januzzi JL, O'Connor CM, Felker GM, Piña IL. Assessing race and ethnicity differences in outcomes based on GDMT and target NT-proBNP in patients with heart failure with reduced ejection fraction: An analysis of the GUIDE-IT study. Progress In Cardiovascular Diseases 2022, 71: 79-85. PMID: 35490873, DOI: 10.1016/j.pcad.2022.04.010.Peer-Reviewed Original ResearchConceptsHeart failure hospitalizationNon-black patientsNT-proBNPBlack patientsFailure hospitalizationHigh riskKansas City Cardiomyopathy Questionnaire overall scorePre-specified subgroup analysisGUIDE-IT trialHigher NYHA classReduced ejection fractionNT-proBNP concentrationsHeart failure therapyNon-Hispanic patientsUsual clinical careImportant baseline covariatesQuality of lifeEthnicity-based differencesHF hospitalizationMore comorbiditiesNYHA classCause mortalityTriple therapyFailure therapyEjection fraction
2021
The Impact of Depression on Outcomes in Patients With Heart Failure and Reduced Ejection Fraction Treated in the GUIDE-IT Trial
Chouairi F, Fuery MA, Mullan CW, Caraballo C, Sen S, Maulion C, Wilkinson ST, Surti T, McCullough M, Miller PE, Pacor J, Leifer ES, Felker GM, Velazquez EJ, Fiuzat M, O'Connor CM, Januzzi JL, Desai NR, Ahmad T. The Impact of Depression on Outcomes in Patients With Heart Failure and Reduced Ejection Fraction Treated in the GUIDE-IT Trial. Journal Of Cardiac Failure 2021, 27: 1359-1366. PMID: 34166799, DOI: 10.1016/j.cardfail.2021.06.008.Peer-Reviewed Original ResearchConceptsGuideline-directed medical therapyReduced ejection fractionAmino-terminal pro-B-type natriuretic peptide levelsPro-B-type natriuretic peptide levelsGUIDE-IT trialNatriuretic peptide levelsHeart failureEjection fractionClinical outcomesPeptide levelsOptimal guideline-directed medical therapyCox proportional hazards regression modelingProportional hazards regression modelingImpact of depressionHistory of depressionCardiovascular deathCause hospitalizationCause mortalityOverall cohortMedical therapyAdverse outcomesTarget dosesPatientsMental healthTime pointsAssociation between Respiratory Failure and Clinical Outcomes in Patients with Acute Heart Failure: Analysis of 5 Pooled Clinical Trials
Miller PE, Van Diepen S, Metkus TS, Alviar CL, Rayner-Hartley E, Rathwell S, Katz JN, Ezekowitz J, Desai NR, Ahmad T. Association between Respiratory Failure and Clinical Outcomes in Patients with Acute Heart Failure: Analysis of 5 Pooled Clinical Trials. Journal Of Cardiac Failure 2021, 27: 602-606. PMID: 33556546, PMCID: PMC8527461, DOI: 10.1016/j.cardfail.2021.01.018.Peer-Reviewed Original ResearchConceptsAcute heart failureBaseline ejection fractionMechanical ventilationRespiratory failureHeart failureClinical trialsClinical outcomesHF etiologyHF rehospitalizationEjection fractionAcute HF admissionBaseline diabetes mellitusHF clinical trialsMechanical ventilation groupMechanical ventilation useProportion of patientsChronic lung diseaseMultivariable logistic regressionOriginal clinical trialsCause mortalityHF admissionsIndex hospitalizationMultivariable adjustmentSmoking historyVentilation group
2020
Impact of Preoperative Lymphopenia on Survival Following Left Ventricular Assist Device Placement
Stawiarski K, Agboola O, Park J, Geirsson A, Jacoby D, Bellumkonda L, Ahmad T, Chou J, Lee F, Mangi A, Bonde P. Impact of Preoperative Lymphopenia on Survival Following Left Ventricular Assist Device Placement. ASAIO Journal 2020, 67: 650-657. PMID: 33074860, DOI: 10.1097/mat.0000000000001289.Peer-Reviewed Original ResearchConceptsAbsolute lymphocyte countCause mortalityLymphopenia groupLeft ventricular assist device patientsVentricular assist device patientsVentricular assist device placementCox proportional hazards modelImpact of lymphopeniaHeart failure populationKaplan-Meier plotsFurther clinical investigationProportional hazards modelLog-rank statisticsDurable LVADPreoperative lymphopeniaLVAD placementLymphocyte countLymphopenic patientsDevice patientsSingle centerPoor outcomePrognostic implicationsALC levelsFailure populationStudy population
2019
LVAD Survival May Be Predicted by Preoperative Lymphopenia
Stawiarski K, Agboola O, Jacoby D, Bellumkonda L, Sugeng L, Ahmad T, Chen M, McCloskey G, Geirsson A, Anwar M, Bonde P. LVAD Survival May Be Predicted by Preoperative Lymphopenia. The Journal Of Heart And Lung Transplantation 2019, 38: s63-s64. DOI: 10.1016/j.healun.2019.01.142.Peer-Reviewed Original ResearchAbsolute lymphocyte countCause mortalityLVAD patientsImmune modulator therapyImpact of lymphopeniaImportant prognostic indicatorCells/μL.Kaplan-Meir plotsLog-rank statisticsPhysiologic stress responseLVAD survivalPreoperative lymphopeniaSplanchnic congestionCox modellingLymphocyte countLymphocyte levelsLymphopenic patientsUnadjusted survivalWorse survivalHeart failurePrognostic roleSerum sodiumSingle centerPatient groupLVAD therapyChloride Homeostasis in End Stage Heart Failure and LVAD Recipients
Stawiarski K, Agboola O, Jacoby D, Bellumkonda L, Ahmad T, Sugeng L, Chen M, McCloskey G, Geirsson A, Anwar M, Bonde P. Chloride Homeostasis in End Stage Heart Failure and LVAD Recipients. The Journal Of Heart And Lung Transplantation 2019, 38: s382-s383. DOI: 10.1016/j.healun.2019.01.974.Peer-Reviewed Original ResearchSerum chloride levelsChloride homeostasisLVAD patientsHeart failureLVAD therapyEnd-stage heart failureCardio-renal axisChronic heart failureStage heart failureChloride levelsLong-term survivalKaplan-Meir plotsLog-rank statisticsL riseCause mortalityLVAD recipientsWorse survivalSingle centerNeurohormonal responsesPrognostic implicationsPrognostic valueLVAD implantsRetrospective analysisGroup ACox model